Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
about
Neuropharmacological effects of Nigella sativaLurasidone for the treatment of bipolar depression: an evidence-based reviewUpdate on the development of lurasidone as a treatment for patients with acute schizophreniaBiophysical Fragment Screening of the β 1 -Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug DesignPrevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia.Quantification of lurasidone, an atypical antipsychotic drug, in rat plasma with high-performance liquid chromatography with tandem mass spectrometry.Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature.Functional interaction of mGlu5 and NMDA receptors in aversive learning in rats.Lurasidone: a new drug in development for schizophrenia.Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex.The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses.Comparative study on induction and effects of surgical menopause in a female rat model: a prospective case control study.ACS chemical neuroscience molecule spotlight on latuda (lurasidone; SM-13,496).Adapalene inhibits the activity of cyclin-dependent kinase 2 in colorectal carcinomaModels and mechanisms of vascular dementia.How to fix a broken clock.ADN-1184 a monoaminergic ligand with 5-HT(6/7) receptor antagonist activity: pharmacological profile and potential therapeutic utility.Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.Atypical antipsychotics: trends in analysis and sample preparation of various biological samples.The atypical antipsychotic class of psychotropic agents. Foreword.Aripiprazole in the treatment of Alzheimer's disease.The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia.Potential use of lurasidone for the treatment of bipolar psychosis.How the pharmacokinetics and receptor-binding profile of lurasidone affect the clinical utility and safety of the drug in the treatment of schizophrenia.Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice.Development of CNS multi-receptor ligands: Modification of known D2 pharmacophoresSynergistic Effect between Maternal Infection and Adolescent Cannabinoid Exposure on Serotonin 5HT1A Receptor Binding in the Hippocampus: Testing the "Two Hit" Hypothesis for the Development of Schizophrenia.Evaluation of the antidepressant, anxiolytic and memory-improving efficacy of aripiprazole and fluoxetine in ethanol-treated rats.Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid.Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia.Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders.Evaluation of antidepressant and memory-improving efficacy of aripiprazole and fluoxetine in alcohol-preferring rats.Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats.Dopamine D4 receptor stimulation contributes to novel object recognition: Relevance to cognitive impairment in schizophrenia.Pharmacological characterisation of a structurally novel α2C-adrenoceptor antagonist ORM-10921 and its effects in neuropsychiatric models.Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats.Effects of risperidone on learning and memory in naive and MK-801-treated rats.
P2860
Q26744248-599136ED-E738-41FB-B6D9-1D80BFAD32DEQ26796437-37F15C58-45F0-4E79-9389-B3119A12151BQ27009585-382D0D38-13B5-4B17-AA54-604C20B3BB0DQ27676919-975F97C3-B8BA-4196-BD85-C8FAED158591Q30524240-05F7F177-308D-4B91-B2A1-C14B2633FC0DQ33605869-76D61880-A9DC-4B35-8E33-6071FA5A6537Q33841168-20986AED-F75A-4415-B16A-EC008C61E2EFQ34542303-43BB2000-9A8C-41A3-B4F4-6B14BC66A952Q34572032-E77EF121-4776-43D7-84AE-F782BC4B3B83Q35005165-F70FF584-33C2-4143-B0D3-38790F8E8535Q35179001-951657F5-0DE7-4FF5-84DA-13DA694CEFABQ35688500-2FF7A48A-2CC3-4CC1-BA2B-7CAF003FB2BDQ35959540-0DED64AD-056E-4C1D-8F68-A6CC4CA20B4FQ36015370-DE025C42-BA55-4BB9-888A-E7BEF4B8F29EQ36224938-9719A026-B491-43F8-B602-C76E48A6F83DQ36244982-3EA71FA1-AB89-4CBE-9CF0-0FF5A646B56AQ37375901-5734A3CD-1B1C-4363-B81F-DED342BB906EQ37585410-114826DE-B4A0-441D-B015-4849FEDA23A9Q37811038-6B1A76C7-E515-4C74-9D50-0F5F7306B82DQ37815561-0099766E-A092-4330-9913-06475934957AQ38005440-390E207A-AFBD-44EA-8AF2-9DB5BEBA6F65Q38007567-4DF5BB6E-5977-48F3-85D8-A41A0CA56603Q38076765-2F436506-6190-4583-B7B4-9B44E7B80C60Q38120295-ADC95CDF-630E-4A79-8E5E-A66B35836D7EQ38336677-BD68C44C-1D9E-4311-B24E-EB90D4C65439Q38546992-02EC8E97-B0BA-4259-9D61-A7B616AE6F6CQ39226303-4F7132AE-681F-4A64-92DB-A644CBB930B5Q40626733-AE735FB4-A7DC-45F7-B677-BA9D7A645E86Q40855546-10CFB98B-6EA8-4316-BD75-95B975FC95E1Q43976588-07E5C951-9649-4371-929E-2B21EB24C78FQ44403456-ED0B81F9-3C63-40D9-8CE6-F7456F1D0668Q45145553-1ADD540D-C96F-476B-B1A7-AAED2AA40CF0Q46038979-63DFD885-F50B-4984-BA67-D26AB8802771Q47970781-E998F846-668B-47F5-8EA6-16B833A7F14BQ48288929-412D600F-09DD-47D0-ADD8-4A6F93F55E68Q48951563-B5C408F7-A773-4653-8985-1208C4A93685Q50590446-71EAF96C-0046-4047-AB15-C162D7736C7FQ50952384-0353D04B-2F34-4CEF-B44B-CD9B575BE93AQ51015703-FB79403E-23DD-40D6-9A46-8624410199F3Q51015748-E5977427-35AF-4B4B-A55C-BA5D5F0F9D32
P2860
Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Lurasidone (SM-13496), a novel ...... he rat passive-avoidance test.
@ast
Lurasidone (SM-13496), a novel ...... he rat passive-avoidance test.
@en
Lurasidone (SM-13496), a novel ...... he rat passive-avoidance test.
@nl
type
label
Lurasidone (SM-13496), a novel ...... he rat passive-avoidance test.
@ast
Lurasidone (SM-13496), a novel ...... he rat passive-avoidance test.
@en
Lurasidone (SM-13496), a novel ...... he rat passive-avoidance test.
@nl
prefLabel
Lurasidone (SM-13496), a novel ...... he rat passive-avoidance test.
@ast
Lurasidone (SM-13496), a novel ...... he rat passive-avoidance test.
@en
Lurasidone (SM-13496), a novel ...... he rat passive-avoidance test.
@nl
P2093
P1476
Lurasidone (SM-13496), a novel ...... he rat passive-avoidance test.
@en
P2093
Kumiko Tokuda
Satoko Toma
Tadashi Ishibashi
Takeo Ishiyama
Yukihiro Ohno
P304
P356
10.1016/J.EJPHAR.2007.06.058
P407
P577
2007-07-10T00:00:00Z